249 related articles for article (PubMed ID: 31423316)
21. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study.
Garg SK; Admane K; Freemantle N; Odawara M; Pan CY; Misra A; Jarek-Martynowa IR; Abbas-Raza S; Mirasol RC; Perfetti R
Endocr Pract; 2015 Feb; 21(2):143-57. PubMed ID: 25297660
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
Oriot P; Jérémie W; Buysschaert M
Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
[TBL] [Abstract][Full Text] [Related]
23. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
Freemantle N; Mauricio D; Giaccari A; Bailey T; Roussel R; Franco D; Berthou B; Pilorget V; Westerbacka J; Bosnyak Z; Bonnemaire M; Cali AMG; Nguyên-Pascal ML; Penfornis A; Perez-Maraver M; Seufert J; Sullivan SD; Wilding J; Wysham C; Davies M
Curr Med Res Opin; 2020 Apr; 36(4):571-581. PubMed ID: 31865758
[No Abstract] [Full Text] [Related]
24. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
25. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
Yki-Järvinen H; Bergenstal RM; Bolli GB; Ziemen M; Wardecki M; Muehlen-Bartmer I; Maroccia M; Riddle MC
Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
Rosenstock J; Diamant M; Aroda VR; Silvestre L; Souhami E; Zhou T; Perfetti R; Fonseca V;
Diabetes Care; 2016 Sep; 39(9):1579-86. PubMed ID: 27284114
[TBL] [Abstract][Full Text] [Related]
27. The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3.
Yale JF; Pettus JH; Brito-Sanfiel M; Lavalle-Gonzalez F; Merino-Trigo A; Stella P; Chevalier S; Buzzetti R
PLoS One; 2018; 13(1):e0190579. PubMed ID: 29370218
[TBL] [Abstract][Full Text] [Related]
28. Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes.
Russell-Jones D; Dauchy A; Delgado E; Dimitriadis G; Frandsen HA; Popescu L; Schultes B; Strojek K; Bonnemaire M; Roborel de Climens A; Davies M
Diabetes Obes Metab; 2019 Jul; 21(7):1615-1624. PubMed ID: 30851006
[TBL] [Abstract][Full Text] [Related]
29. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
[TBL] [Abstract][Full Text] [Related]
30. In Silico Examination of Initiation of Long-Acting Insulin Analogs Toujeo Compared to Lantus Under 3 Dosing Titration Rules in Virtual Type 2 Diabetes Subjects.
Sieber J; Weinheimer M; Kongable G; Riddle S; Chang YY; Flacke F
J Diabetes Sci Technol; 2020 Sep; 14(5):898-907. PubMed ID: 31288531
[TBL] [Abstract][Full Text] [Related]
31. Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial.
Yang W; Ma J; Yuan G; Li L; Zhang M; Lu Y; Ye X; Song W; Liu M; Wu J; Chen R; Li Y; Zhang X; Cui N; Yang J
Diabetes Obes Metab; 2019 Aug; 21(8):1973-1977. PubMed ID: 30938035
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study).
Odawara M; Matsuhisa M; Hirose T; Koshida R; Senda M; Tanaka Y; Terauchi Y
Expert Opin Pharmacother; 2020 Oct; 21(14):1771-1780. PubMed ID: 32693663
[TBL] [Abstract][Full Text] [Related]
33. Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India.
Ghosal S; Sinha B; Gangopadhyay KK
Diabetes Metab Syndr; 2016; 10(3):161-5. PubMed ID: 26822462
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A
Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
[No Abstract] [Full Text] [Related]
35. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
Lingvay I; Chao J; Dalal MR; Meneghini LF
Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
[TBL] [Abstract][Full Text] [Related]
37. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
Riddle MC; Yki-Järvinen H; Bolli GB; Ziemen M; Muehlen-Bartmer I; Cissokho S; Home PD
Diabetes Obes Metab; 2015 Sep; 17(9):835-42. PubMed ID: 25846721
[TBL] [Abstract][Full Text] [Related]
38. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
[TBL] [Abstract][Full Text] [Related]
40. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
